United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics (NASDAQ:UTHR) reported strong Q2 2025 financial results with record total revenue of $798.6 million, up 12% year-over-year, marking 12 consecutive quarters of double-digit growth. The company's Board authorized a $1 billion share repurchase program through March 2026.

Key highlights include Tyvaso DPI's record revenue of $315.2 million (22% growth), strong performance from Nebulized Tyvaso, Orenitram, and Unituxin. Net income reached $309.5 million ($6.41 per diluted share). The company expects continued double-digit revenue growth, supported by its commercial portfolio and late-stage pipeline in pulmonary fibrosis and pulmonary hypertension.

Important upcoming catalysts include the TETON 2 study results in September 2025 for idiopathic pulmonary fibrosis and ADVANCE OUTCOMES study data in H1 2026 for pulmonary arterial hypertension.

United Therapeutics (NASDAQ: UTHR) has scheduled its second quarter 2025 financial results announcement for Wednesday, July 30, 2025, before market open. The company will release detailed quarterly results via press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time.

The webcast will be available through the company's investor relations website at ir.unither.com/events-and-presentations, with a rebroadcast accessible for one year afterward. United Therapeutics operates as a public benefit corporation (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

United Therapeutics (NASDAQ:UTHR) and Intermountain Health have achieved a groundbreaking milestone with the world's first patient treatment using miroliverELAP®, a bioengineered external liver assist product. The procedure was performed at Intermountain Medical Center in Murray, Utah, on a patient with liver failure who wasn't eligible for transplant.

MiroliverELAP, developed by UTHR subsidiary Miromatrix Medical, consists of a single-use MIRO-001 bioengineered liver and extracorporeal blood circuit. The technology uses a decellularized porcine liver scaffold combined with human endothelial and liver cells. This Phase 1 study represents the first human clinical trial of a manufactured organ alternative, addressing a critical need as approximately 30% of acute liver failure patients die without access to liver transplants.

United Therapeutics (NASDAQ: UTHR) announced completion of enrollment for its phase 3 ADVANCE OUTCOMES study of ralinepag, a potential first-in-class once-daily oral prostacyclin agonist for pulmonary arterial hypertension (PAH). The study enrolled 728 participants, with top-line data expected in H1 2026. Previous phase 2 results showed promising efficacy with a 29.8% reduction in pulmonary vascular resistance compared to placebo. In the open-label extension study, ralinepag demonstrated sustained benefits, including a significant 36.3-meter improvement in six-minute walk distance and maintained stable functional class in over 85% of participants after two years. The drug also showed significant improvements in hemodynamic measures and maintained a manageable side effect profile.

United Therapeutics reported strong Q1 2025 financial results with total revenues reaching $794.4 million, marking a 17% increase from Q1 2024. The company's flagship product Tyvaso led growth with total revenues of $466.3 million, up 25% year-over-year.

Key highlights include net income of $322.2 million and earnings per diluted share of $6.63. Tyvaso DPI showed exceptional performance with a 33% revenue increase to $302.5 million. The growth was driven by increased patient numbers and Medicare Part D benefit redesign implementation.

The company announced progress in their organ transplant alternatives program, with planned FDA applications for UHeart and UThymoKidney products. They also expect results from the TETON 2 trial in idiopathic pulmonary fibrosis and plan to commence UKidney human clinical studies.

United Therapeutics (UTHR) has announced its participation in the American Thoracic Society (ATS) International Conference in San Francisco, May 16-21, 2025, where it will present clinical data across its commercial and development portfolio.

Key presentations include interim long-term data from the ralinepag phase 3 ADVANCE EXTENSION open-label study and preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis. The company will showcase research through various sessions, including thematic posters, mini-symposia, and discussion sessions.

The company is also sponsoring several events including the Respiratory Innovation Summit, the ATS Research Program Benefit Networking Event, and hosting the Jenesis Innovative Research Awards™ Ceremony.

United Therapeutics (NASDAQ: UTHR) has announced it will release its first quarter 2025 financial results before market opening on Wednesday, April 30, 2025. The company will issue a detailed press release at approximately 6:30 a.m. Eastern Time, followed by a public webcast at 9:00 a.m. Eastern Time.

The webcast will be available through the company's investor relations website and will remain accessible for replay for one year. United Therapeutics operates as a public benefit (PBC), focusing on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.

United Therapeutics (UTHR) announced the presentation of ten posters and presentations across its commercial and development portfolio at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting taking place April 27-30, 2025 in Boston.

The presentations cover various topics including xenotransplantation developments, pharmacokinetic studies of Ralinepag, cardiac xenotransplantation outcomes, and pulmonary hypertension research. Key highlights include studies on multi-gene-edited pig lungs, pig-to-baboon lung transplantation, and safety data on low-dose oral Treprostinil in PH-HFpEF patients.

The company will also host a sponsored symposium titled 'The Pros, The Cons, the Wicked Good EVLP Debates' featuring experts from leading medical institutions discussing ex vivo lung perfusion.

United Therapeutics (NASDAQ: UTHR) has been recognized as one of the Fortune 100 Best Companies to Work For in 2025, ranking #73 on the prestigious list. The recognition comes from Great Place to Work® and Fortune magazine, based on confidential feedback from over 1.3 million U.S. employees.

As the first publicly-traded biotech company to become a public benefit (PBC), United Therapeutics focuses on developing novel pharmaceutical therapies and expanding transplantable organ availability. The company's placement on the list reflects its commitment to creating a high-trust workplace environment, measured through Great Place To Work's Trust Index™ Survey.

Michael Benkowitz, President & COO, emphasized the company's goal of being a destination employer, while Alyssa Friedrich, EVP and Chief People Officer, highlighted their focus on creating an environment where employees feel valued and inspired.